Brian Daniels, M.D.

Chairman

Brian Daniels, M.D., is Chairman of Artiva’s Board of Directors and a Partner at 5AM Ventures. He joined 5AM Ventures as a Venture Partner in 2014 and transitioned to Partner in 2018. Dr. Daniels previously spent more than two decades in clinical drug development, including leading the Development and Medical Affairs at Bristol-Myers Squibb for the last ten years. He directed the development of numerous innovative medicines that have contributed to the improvement for patients across a range of serious diseases. These include: ORENCIA and NULOJIX in immunology/transplant, REYATAZ, DAKLINZA and BARACLUDE in virology, ONGLYZA, FARXIGA and MYALEPT in metabolics, ELIQUIS in cardiovascular and YERVOY, OPDIVO, SPRYCEL and IXEMPRA in oncology. Dr. Daniels is currently a Director at these 5AM companies: Spyryx Bioscience, Nohla Therapeutics, Rarecyte, and Ideaya Biosciences (independent). He leads the Clinical Advisory Board for Aprea Therapeutics and also served on the Scientific Advisory Board of Novira. Dr. Daniels received B.S. and M.S. degrees from MIT and his M.D. from Washington University in St. Louis. He trained in internal medicine at New York Hospital and rheumatology/immunology at UCSF. Dr. Daniels is based in the San Francisco office.

  • Twitter
  • LinkedIn

Privacy Policy  |  Terms
© Artiva Biotherapeutics, Inc., 2021